These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6217268)

  • 1. Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinemia after TP5 treatment.
    Williams RC; Montano JD; Bankhurst AD
    J Lab Clin Med; 1983 Jan; 101(1):152-60. PubMed ID: 6217268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin.
    Pozzilli P; Visalli N; Cavallo MG; Beales P; Negri M; Ghirlanda G; Papa V; Andreani D
    Diabetes Res; 1987 Oct; 6(2):51-6. PubMed ID: 2962799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
    Levinsky RJ; Davies EG; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):273-6. PubMed ID: 6360239
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of Di George syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function.
    Joffe MI; Sochett E; Pettifor JM; Rabson AR
    J Clin Lab Immunol; 1982 May; 8(1):69-73. PubMed ID: 6212686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic use of TP5 (thymopoietin 32-36) in sarcoidosis of the skin.
    Thivolet J; Faure M; Nicolas JF; Mauduit G; Claudy A
    Clin Immunol Immunopathol; 1983 Mar; 26(3):350-60. PubMed ID: 6347481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
    Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G
    Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of recurrent herpes simplex with thymopoietin-pentapeptide].
    Djawari D; Bolla K; Haneke E
    Dtsch Med Wochenschr; 1984 Mar; 109(13):496-8. PubMed ID: 6368167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Model for acquired immunodeficiency caused by anesthesia and surgical procedures. Effect of treatment with thymopoietin pentapeptide (TP5)].
    Auteri A; D'Aniello C; Falotico N; Saletti M; Di Perri T
    Recenti Prog Med; 1986 Sep; 77(9):423-8. PubMed ID: 3541085
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of thymopentin treatment on the relapse rate in frequently relapsing herpes simplex virus infections.
    Haneke E; Bolla K; Degreef H; Djawari D; Demaubeuge J; Molin L; Panconesi E; Schöpf E; Stengel R; Stingl G
    Int J Clin Pharmacol Res; 1984; 4(6):439-43. PubMed ID: 6085327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
    [No Abstract]   [Full Text] [Related]  

  • 12. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
    Hamilton G; Zöch G; Rath T; Meissl G
    Prog Clin Biol Res; 1989; 308():995-9. PubMed ID: 2528748
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy.
    Barcellini W; Meroni PL; Frasca D; Sguotti C; Borghi MO; Uberti-Foppa C; Buzzetti P; Lazzarin A; Doria G; Moroni M
    Clin Exp Immunol; 1987 Mar; 67(3):537-43. PubMed ID: 3301099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymopentin in chronic Trichophyton rubrum infection.
    Molin L; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():135-8. PubMed ID: 3898286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study.
    DeMaubeuge J; Haneke E; Djawari D; Wolff K; Stingl G; Molin L; Schöpf E; Stengel R; Degreef H; Panconesi E
    Surv Immunol Res; 1985; 4 Suppl 1():30-6. PubMed ID: 2863860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.
    Lau CY; Wang EY; Goldstein G
    Cell Immunol; 1982 Jan; 66(2):217-32. PubMed ID: 6802504
    [No Abstract]   [Full Text] [Related]  

  • 17. Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia.
    White WB; Ballow M
    N Engl J Med; 1985 Jan; 312(4):198-202. PubMed ID: 3155562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymopentin in active rheumatoid arthritis. An open, monitored study in 16 patients.
    Franchimont P; Hauwaert C; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():81-6. PubMed ID: 3898297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressor cell phenotype deficiency and its restoration by thymopoietin pentapeptide in atopic dermatitis.
    Kang K; Strannegård O; Strannegård IL; Cooper K; Hanifin JM
    Monogr Allergy; 1983; 18():181-5. PubMed ID: 6227816
    [No Abstract]   [Full Text] [Related]  

  • 20. Preliminary results on clinical and immunological effects of thymopentin in AIDS.
    Clumeck N; van de Perre P; Mascart-Lemone F; Cran S; Bolla K; Duchateau J
    Int J Clin Pharmacol Res; 1984; 4(6):459-63. PubMed ID: 6398315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.